Tags

Type your tag names separated by a space and hit enter

Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective.
Am J Manag Care. 2001 Aug; 7(8):809-18.AJ

Abstract

BACKGROUND

The number of patients with Alzheimer's disease (AD) and related dementia treated in managed care organizations (MCOs) is increasing, and this trend is expected to continue. Therefore, it is critical that MCOs develop disease management strategies for this population.

OBJECTIVE

To review the literature on the prevalence, costs, and treatment of AD and related dementia.

STUDY DESIGN

Review of published articles from MEDLINE and peer-reviewed journals.

RESULTS

Prevalence of AD and related dementia is approximately 5.7% among those aged 65 and older. Prevalence data from claims-based studies of AD in managed care are lower, ranging from 0.55% to 0.83%. Costs for formal care average $27,672 per patient annually, with long-term care being the most costly component. Annual costs for informal care are estimated to be $10,400 to $34,517 per patient. Additional costs associated with AD include lost wages and productivity of patients and caregivers and costs associated with increased morbidity of caregivers. Donepezil treatment is well tolerated and has been extensively tested and evaluated in clinical settings. Early diagnosis and treatment of AD with donepezil has been shown to slow cognitive decline in AD. Although study findings regarding the cost offsets of donepezil-treated patients to date are mixed, there is a growing body of evidence to support the inclusion of this and other therapies into an MCO's AD treatment armamentarium.

CONCLUSIONS

It is unlikely that MCOs will escape the increased prevalence and costs associated with AD. Opportunities exist through patient management programs targeted toward early diagnosis, effective use of medications, control of comorbidities, and patient and family support to partially offset these costs while providing quality patient care.

Authors+Show Affiliations

Institute for Health and Aging, University of California at San Francisco, 3333 California Street, Suite 340, San Francisco, CA 94118, USA. rice@itsa.ucsf.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

11519239

Citation

Rice, D P., et al. "Prevalence, Costs, and Treatment of Alzheimer's Disease and Related Dementia: a Managed Care Perspective." The American Journal of Managed Care, vol. 7, no. 8, 2001, pp. 809-18.
Rice DP, Fillit HM, Max W, et al. Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. Am J Manag Care. 2001;7(8):809-18.
Rice, D. P., Fillit, H. M., Max, W., Knopman, D. S., Lloyd, J. R., & Duttagupta, S. (2001). Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. The American Journal of Managed Care, 7(8), 809-18.
Rice DP, et al. Prevalence, Costs, and Treatment of Alzheimer's Disease and Related Dementia: a Managed Care Perspective. Am J Manag Care. 2001;7(8):809-18. PubMed PMID: 11519239.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. AU - Rice,D P, AU - Fillit,H M, AU - Max,W, AU - Knopman,D S, AU - Lloyd,J R, AU - Duttagupta,S, PY - 2001/8/25/pubmed PY - 2001/10/19/medline PY - 2001/8/25/entrez SP - 809 EP - 18 JF - The American journal of managed care JO - Am J Manag Care VL - 7 IS - 8 N2 - BACKGROUND: The number of patients with Alzheimer's disease (AD) and related dementia treated in managed care organizations (MCOs) is increasing, and this trend is expected to continue. Therefore, it is critical that MCOs develop disease management strategies for this population. OBJECTIVE: To review the literature on the prevalence, costs, and treatment of AD and related dementia. STUDY DESIGN: Review of published articles from MEDLINE and peer-reviewed journals. RESULTS: Prevalence of AD and related dementia is approximately 5.7% among those aged 65 and older. Prevalence data from claims-based studies of AD in managed care are lower, ranging from 0.55% to 0.83%. Costs for formal care average $27,672 per patient annually, with long-term care being the most costly component. Annual costs for informal care are estimated to be $10,400 to $34,517 per patient. Additional costs associated with AD include lost wages and productivity of patients and caregivers and costs associated with increased morbidity of caregivers. Donepezil treatment is well tolerated and has been extensively tested and evaluated in clinical settings. Early diagnosis and treatment of AD with donepezil has been shown to slow cognitive decline in AD. Although study findings regarding the cost offsets of donepezil-treated patients to date are mixed, there is a growing body of evidence to support the inclusion of this and other therapies into an MCO's AD treatment armamentarium. CONCLUSIONS: It is unlikely that MCOs will escape the increased prevalence and costs associated with AD. Opportunities exist through patient management programs targeted toward early diagnosis, effective use of medications, control of comorbidities, and patient and family support to partially offset these costs while providing quality patient care. SN - 1088-0224 UR - https://www.unboundmedicine.com/medline/citation/11519239/Prevalence_costs_and_treatment_of_Alzheimer's_disease_and_related_dementia:_a_managed_care_perspective_ L2 - https://www.ajmc.com/pubMed.php?pii=501 DB - PRIME DP - Unbound Medicine ER -